{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T21:01:59Z","timestamp":1777064519830,"version":"3.51.4"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,6]],"date-time":"2023-03-06T00:00:00Z","timestamp":1678060800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["GNT1130301"],"award-info":[{"award-number":["GNT1130301"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ijidonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Infectious Diseases"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.ijid.2023.03.010","type":"journal-article","created":{"date-parts":[[2023,3,9]],"date-time":"2023-03-09T03:06:51Z","timestamp":1678331211000},"page":"189-195","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Ultra-short course, high-dose primaquine to prevent Plasmodium vivax infection following uncomplicated pediatric malaria: A randomized, open-label, non-inferiority trial of early versus delayed treatment"],"prefix":"10.1016","volume":"130","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8602-2734","authenticated-orcid":false,"given":"Sze-Ann","family":"Woon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9792-7838","authenticated-orcid":false,"given":"Brioni R.","family":"Moore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moses","family":"Laman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paula","family":"Tesine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lina","family":"Lorry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernadine","family":"Kasian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Phantica","family":"Yambo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gumul","family":"Yadi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"Pomat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3850-1778","authenticated-orcid":false,"given":"Kevin T.","family":"Batty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8276-6784","authenticated-orcid":false,"given":"Sam","family":"Salman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leanne J.","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0749-7411","authenticated-orcid":false,"given":"Timothy M.E.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4334-5351","authenticated-orcid":false,"given":"Laurens","family":"Manning","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijid.2023.03.010_bib0001","series-title":"Guidelines for the treatment of malaria","year":"2015"},{"key":"10.1016\/j.ijid.2023.03.010_bib0002","series-title":"WHO guidelines for malaria","year":"2021"},{"key":"10.1016\/j.ijid.2023.03.010_bib0003","series-title":"Standard treatment for common illnesses of children in Papua New Guinea","year":"2016"},{"key":"10.1016\/j.ijid.2023.03.010_bib0004","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s12936-020-3121-3","article-title":"Optimal timing of primaquine to reduce Plasmodium falciparum gametocyte carriage when co-administered with artemether-lumefantrine","volume":"19","author":"Shekalaghe","year":"2020","journal-title":"Malar J"},{"key":"10.1016\/j.ijid.2023.03.010_bib0005","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1186\/s12916-015-0535-9","article-title":"Randomized trial of primaquine hypnozoitocidal efficacy when administered with artemisinin-combined blood schizontocides for radical cure of Plasmodium vivax in Indonesia","volume":"13","author":"Nelwan","year":"2015","journal-title":"BMC Med"},{"key":"10.1016\/j.ijid.2023.03.010_bib0006","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002928","article-title":"The efficacy of dihydroartemisinin-piperaquine and artemether-lumefantrine with and without primaquine on Plasmodium vivax recurrence: a systematic review and individual patient data meta-analysis","volume":"16","author":"Commons","year":"2019","journal-title":"PLoS Med"},{"key":"10.1016\/j.ijid.2023.03.010_bib0007","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002299","article-title":"Comparison of artemether-lumefantrine and chloroquine with and without primaquine for the treatment of Plasmodium vivax infection in Ethiopia: a randomized controlled trial","volume":"14","author":"Abreha","year":"2017","journal-title":"PLoS Med"},{"key":"10.1016\/j.ijid.2023.03.010_bib0008","doi-asserted-by":"crossref","first-page":"105","DOI":"10.2165\/00003088-199937020-00002","article-title":"Clinical pharmacokinetics and pharmacodynamics and pharmacodynamics of artemether-lumefantrine","volume":"37","author":"White","year":"1999","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.ijid.2023.03.010_bib0009","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ijpddr.2020.12.004","article-title":"Primaquine for Plasmodium vivax radical cure: what we do not know and why it matters","volume":"15","author":"Popovici","year":"2021","journal-title":"Int J Parasitol Drugs Drug Resist"},{"key":"10.1016\/j.ijid.2023.03.010_bib0010","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s12936-018-2190-z","article-title":"Primaquine ineligibility in anti-relapse therapy of Plasmodium vivax malaria: the problem of G6PD deficiency and cytochrome P-450 2D6 polymorphisms","volume":"17","author":"Baird","year":"2018","journal-title":"Malar J"},{"key":"10.1016\/j.ijid.2023.03.010_bib0011","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2018.1449","article-title":"Association of impaired cytochrome P450 2D6 activity genotype and phenotype with therapeutic efficacy of primaquine treatment for latent Plasmodium vivax malaria","volume":"1","author":"Baird","year":"2018","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.ijid.2023.03.010_bib0012","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s12936-017-2139-7","article-title":"CYP2D6 activity and the risk of recurrence of Plasmodium vivax malaria in the Brazilian Amazon: a prospective cohort study","volume":"17","author":"Brasil","year":"2018","journal-title":"Malar J"},{"key":"10.1016\/j.ijid.2023.03.010_bib0013","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pharmthera.2016.03.011","article-title":"Primaquine pharmacology in the context of CYP 2D6 pharmacogenomics: current state of the art","volume":"161","author":"Marcsisin","year":"2016","journal-title":"Pharmacol Ther"},{"issue":"7","key":"10.1016\/j.ijid.2023.03.010_bib0014","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0160172","article-title":"Variation in human cytochrome P-450 drug-metabolism genes: a gateway to the understanding of Plasmodium vivax relapses","volume":"11","author":"Silvino","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.ijid.2023.03.010_bib0015","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02056-19","article-title":"Novel insights into Plasmodium vivax therapeutic failure: CYP2D6 activity and time of exposure to malaria modulate the risk of recurrence","volume":"64","author":"Silvino","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijid.2023.03.010_bib0016","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1128\/AAC.01437-13","article-title":"Pharmacokinetic properties of single-dose primaquine in Papua New Guinean children: feasibility of abbreviated high-dose regimens for radical cure of vivax malaria","volume":"58","author":"Moore","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijid.2023.03.010_bib0017","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001891","article-title":"Strategies for understanding and reducing the Plasmodium vivax and Plasmodium ovale hypnozoite reservoir in Papua New Guinean children: a randomised placebo-controlled trial and mathematical model","volume":"12","author":"Robinson","year":"2015","journal-title":"PLoS Med"},{"key":"10.1016\/j.ijid.2023.03.010_bib0018","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001773","article-title":"Artemisinin-naphthoquine versus artemether-lumefantrine for uncomplicated malaria in Papua New Guinean children: an open-label randomized trial","volume":"11","author":"Laman","year":"2014","journal-title":"PLoS Med"},{"key":"10.1016\/j.ijid.2023.03.010_bib0019","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003393","article-title":"The risk of Plasmodium vivax parasitaemia after P. falciparum malaria: an individual patient data meta-analysis from the WorldWide Antimalarial Resistance Network","volume":"17","author":"Hossain","year":"2020","journal-title":"PLoS Med"},{"key":"10.1016\/j.ijid.2023.03.010_bib0020","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S1473-3099(18)30596-6","article-title":"Risk of Plasmodium vivax parasitaemia after Plasmodium falciparum infection: a systematic review and meta-analysis","volume":"19","author":"Commons","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijid.2023.03.010_bib0021","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/S1473-3099(21)00358-3","article-title":"Supervised versus unsupervised primaquine radical cure for the treatment of falciparum and vivax malaria in Papua, Indonesia: a cluster-randomised, controlled, open-label superiority trial","volume":"22","author":"Poespoprodjo","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijid.2023.03.010_bib0022","doi-asserted-by":"crossref","first-page":"e29203","DOI":"10.1371\/journal.pone.0029203","article-title":"Features and prognosis of severe malaria caused by Plasmodium falciparum, Plasmodium vivax and mixed Plasmodium species in Papua New Guinean children","volume":"6","author":"Manning","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.ijid.2023.03.010_bib0023","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/0166-6851(93)90050-8","article-title":"Identification of the four human malaria parasite species in field samples by the polymerase chain reaction and detection of a high prevalence of mixed infections","volume":"58","author":"Snounou","year":"1993","journal-title":"Mol Biochem Parasitol"},{"key":"10.1016\/j.ijid.2023.03.010_bib0024","doi-asserted-by":"crossref","first-page":"326","DOI":"10.5694\/j.1326-5377.2009.tb02425.x","article-title":"Non-inferiority trials: determining whether alternative treatments are good enough","volume":"190","author":"Scott","year":"2009","journal-title":"Med J Aust"},{"key":"10.1016\/j.ijid.2023.03.010_bib0025","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa0804915","article-title":"A trial of combination antimalarial therapies in children from Papua New Guinea","volume":"359","author":"Karunajeewa","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijid.2023.03.010_bib0026","series-title":"R: a language and environment for statistical computing","year":"2018"},{"key":"10.1016\/j.ijid.2023.03.010_bib0027","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1093\/cid\/ciy735","article-title":"Chloroquine versus dihydroartemisinin-piperaquine with standard high-dose primaquine given either for 7 days or 14 days in Plasmodium vivax malaria","volume":"68","author":"Chu","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2023.03.010_bib0028","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/S0140-6736(19)31285-1","article-title":"Short-course primaquine for the radical cure of Plasmodium vivax malaria: a multicentre, randomised, placebo-controlled non-inferiority trial","volume":"394","author":"Taylor","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.ijid.2023.03.010_bib0029","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s40272-014-0076-2","article-title":"Comparison between paediatric and adult suspected adverse drug reactions reported to the European Medicines Agency: implications for pharmacovigilance","volume":"16","author":"Blake","year":"2014","journal-title":"Paediatr Drugs"},{"key":"10.1016\/j.ijid.2023.03.010_bib0030","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s12936-021-04032-2","article-title":"Safety of dihydroartemisinin-piperaquine versus artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria among children in Africa: a systematic review and meta-analysis of randomized control trials","volume":"21","author":"Assefa","year":"2022","journal-title":"Malar J"},{"key":"10.1016\/j.ijid.2023.03.010_bib0031","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1186\/1475-2875-11-260","article-title":"Clinical tolerability of artesunate-amodiaquine versus comparator treatments for uncomplicated falciparum malaria: an individual-patient analysis of eight randomized controlled trials in sub-Saharan Africa","volume":"11","author":"Zwang","year":"2012","journal-title":"Malar J"},{"key":"10.1016\/j.ijid.2023.03.010_bib0032","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1186\/1475-2875-13-144","article-title":"Geographical variation in Plasmodium vivax relapse","volume":"13","author":"Battle","year":"2014","journal-title":"Malar J"},{"key":"10.1016\/j.ijid.2023.03.010_bib0033","article-title":"Primaquine for preventing relapse in people with Plasmodium vivax malaria treated with chloroquine","volume":"2013","author":"Galappaththy","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ijid.2023.03.010_bib0034","doi-asserted-by":"crossref","DOI":"10.1016\/j.parint.2021.102512","article-title":"Antimalarials for children with Plasmodium vivax infection: current status, challenges, and research priorities","volume":"87","author":"Woon","year":"2022","journal-title":"Parasitol Int"}],"container-title":["International Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971223000863?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971223000863?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T08:11:32Z","timestamp":1761120692000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1201971223000863"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":34,"alternative-id":["S1201971223000863"],"URL":"https:\/\/doi.org\/10.1016\/j.ijid.2023.03.010","relation":{},"ISSN":["1201-9712"],"issn-type":[{"value":"1201-9712","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ultra-short course, high-dose primaquine to prevent Plasmodium vivax infection following uncomplicated pediatric malaria: A randomized, open-label, non-inferiority trial of early versus delayed treatment","name":"articletitle","label":"Article Title"},{"value":"International Journal of Infectious Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijid.2023.03.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.","name":"copyright","label":"Copyright"}]}}